Patents by Inventor Stefan Steidl

Stefan Steidl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220144965
    Abstract: The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of anti-PLA2R positive membranous glomerulonephropathy.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Inventors: Daniel KLUNKER, Rainer BOXHAMMER, Stefan HÄRTLE, Stefan STEIDL, Tiantom JARUTAT
  • Publication number: 20210347879
    Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: May 7, 2021
    Publication date: November 11, 2021
    Inventors: Stefan STEIDL, Elisabeth THOMASSEN-WOLF
  • Patent number: 11028165
    Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 8, 2021
    Assignee: MORPHOSYS AG
    Inventors: Stefan Steidl, Elisabeth Thomassen-Wolf
  • Publication number: 20210130451
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 6, 2021
    Applicant: MORPHOSYS AG
    Inventors: Stefan HARTLE, Stephane LECLAIR, Amgad SHEBL, Stefan STEIDL, Bodo BROCKS, Daniela Della DUCATA, Kai ROSPORT
  • Patent number: 10913792
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 9, 2021
    Assignee: Morphosys AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
  • Publication number: 20200352975
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: April 3, 2020
    Publication date: November 12, 2020
    Inventors: Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
  • Publication number: 20200353077
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Application
    Filed: April 3, 2020
    Publication date: November 12, 2020
    Inventors: Jutta AMERSDORFFER, Stefan STEIDL, Mark WINDERLICH, Susanne KROHN, Lisa ROJKJAER
  • Publication number: 20200024340
    Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: June 17, 2019
    Publication date: January 23, 2020
    Applicant: MORPHOSYS AG
    Inventors: Stefan Steidl, Elisabeth THOMASSEN-WOLF
  • Patent number: 10377820
    Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: August 13, 2019
    Assignee: Morphosys AG
    Inventors: Stefan Steidl, Elisabeth Thomassen-Wolf
  • Publication number: 20180258181
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: March 5, 2018
    Publication date: September 13, 2018
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Antje KAHNERT, David LIGHT, Doug SCHNEIDER, Renate PARRY, Noboru SATOZAWA, Tara HEITNER, Stefan STEIDL, Ulrike SCHUBERT
  • Publication number: 20180237531
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 23, 2018
    Inventors: Stefan STEIDL, John Allan HAMILTON, Andrew David COOK
  • Publication number: 20180230208
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: January 26, 2018
    Publication date: August 16, 2018
    Applicant: Morphosys Ag
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl
  • Patent number: 10005840
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 26, 2018
    Assignees: MORPHOSYS AG, THE UNIVERSITY OF MELBOURNE
    Inventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
  • Patent number: 9751939
    Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: September 5, 2017
    Assignee: Morphosys AG
    Inventors: Stefan Steidl, Elisabeth Thomassen-Wolf
  • Publication number: 20170218061
    Abstract: The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: December 21, 2016
    Publication date: August 3, 2017
    Applicant: MORPHOSYS AG
    Inventors: Stefan Steidl, Elisabeth Thomassen-Wolf
  • Publication number: 20160185867
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 30, 2016
    Inventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
  • Patent number: 9243066
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: January 26, 2016
    Assignees: University of Melbourne, Morpho Sys AG
    Inventors: Stefan Steidl, John Allan Hamilton, Andrew David Cook
  • Publication number: 20150259433
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: March 11, 2015
    Publication date: September 17, 2015
    Inventors: Antje KAHNERT, David LIGHT, Doug SCHNEIDER, Renate PARRY, Noboru SATOZAWA, Tara HEITNER, Stefan STEIDL, Ulrike SCHUBERT
  • Publication number: 20150246969
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: September 19, 2013
    Publication date: September 3, 2015
    Applicant: MORPHOSYS AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl
  • Patent number: 9023351
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: May 5, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Antje Kahnert, David Light, Doug Schneider, Renate Parry, Noboru Satozawa, Tara Renee Heitner Hansen, Stefan Steidl, Ulrike Schubert